Comparison
Omega-3 (EPA/DHA) vs Testosterone
Side-by-side of Omega-3 (EPA/DHA) and Testosterone. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Testosterone
Testosterone replacement therapy for hypogonadism: TRAVERSE 2023 cardiovascular data, cypionate dosing, body composition gains, Schedule III status.
Effects at a glance
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Testosterone
- •Primary androgen; FDA approved for hypogonadism with confirmed deficiency and symptoms
- •Testosterone Trials (2016) showed sexual function and bone density improvements in older hypogonadal men
- •TRAVERSE 2023 (n=5,246) found non-inferiority on MACE versus placebo, with higher AF and PE rates
- •Schedule III controlled substance in US; WADA banned in sport
- •Aromatizes to estradiol; converts to DHT via 5-alpha reductase; both metabolites matter clinically
- •Erythrocytosis (HCT above 54%) affects 5 to 25% of users and is the most common dose-limiting effect
Side-by-side
| Attribute | Omega-3 (EPA/DHA) | Testosterone |
|---|---|---|
| Category | supplement | hormone |
| Also known as | fish oil, EPA, DHA, marine omega-3 | TRT, testosterone replacement therapy, testosterone cypionate, testosterone enanthate, Androgel, Testim |
| Half-life (hr) ↗ | 48 | 192 |
| Typical dose (mg) ↗ | 2000 | 150 |
| Dosing frequency | 1 to 2 times daily with food | weekly to twice-weekly (cypionate/enanthate IM or SC); daily (topical, oral); every 3 to 6 months (pellet) |
| Routes | oral | intramuscular, subcutaneous, topical, buccal, subcutaneous (pellet), oral |
| Onset (hr) | 4 | 24 |
| Peak (hr) | 12 | 72 |
| Molecular weight | 302.45 | 288.42 |
| Molecular formula | C20H30O2 (EPA); C22H32O2 (DHA) | C19H28O2 |
| Mechanism | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. | Androgen receptor agonist driving anabolic gene transcription in muscle, bone, brain, and androgen-sensitive tissue. Aromatized to estradiol and 5-alpha-reduced to DHT, both with distinct downstream effects. |
| Legal status | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia | Schedule III controlled substance (US); WADA banned |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled | Schedule III |
| Pregnancy | Recommended at 200 to 600 mg DHA/day for fetal development | Category X; contraindicated in pregnancy (virilizing effect on female fetus) |
| CAS | 10417-94-4 | 58-22-0 |
| PubChem CID | 446284 | 6013 |
| Wikidata | Q207688 | Q150726 |
Safety profile
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Testosterone
Common side effects
- erythrocytosis
- acne
- oily skin
- fluid retention
- increased body hair
- fertility suppression
- injection-site reactions
Contraindications
- active prostate cancer
- active breast cancer
- untreated severe sleep apnea
- untreated severe BPH
- uncontrolled heart failure
- polycythemia at baseline
Interactions
- warfarin: may potentiate anticoagulant effect; monitor INR(moderate)
- insulin: may improve insulin sensitivity; monitor glucose in diabetics(moderate)
- 5-alpha reductase inhibitors (finasteride): blocks DHT conversion; reduces some androgen effects(moderate)
- aromatase inhibitors (anastrozole): lowers estradiol; risk of over-suppression(moderate)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Testosterone is the right call when one of the conditionals below applies.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is healthspan extension, pick Omega-3 (EPA/DHA).
- → If your priority is hormonal optimization, pick Testosterone.
- → If your priority is sexual function, pick Testosterone.
Edge case: If you want to avoid controlled substance, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Testosterone only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Omega-3 (EPA/DHA) and Testosterone?
Omega-3 (EPA/DHA) and Testosterone differ in category (supplement vs hormone), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Omega-3 (EPA/DHA) or Testosterone?
Omega-3 (EPA/DHA) half-life is 48 hours; Testosterone half-life is 192 hours.
Can you stack Omega-3 (EPA/DHA) with Testosterone?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper